Lynk Reports Sustained Phase III Results for Zemprocitinib
Hangzhou, China; Shanghai, China; and Boston, Massachusetts, USA, October 27, 2026 Lynk Pharmaceuticals Co., Ltd. has announced positive long-term...
inflammatory disease
Advertisement
Johnson & Johnson Reports TREMFYA Axial PsA Study Data
Spring House, Pennsylvania, September 25, 2026 Johnson & Johnson announced topline results from the Phase 4 STAR study evaluating...
Oruka Reports Positive Week 28 ORKA-001 Psoriasis Data
MENLO PARK, Calif. — September 23, 2026 Oruka Therapeutics announced positive Week 28 data from the ongoing EVERLAST-A Phase...
Alfasigma Gains Positive CHMP Opinion for Filgotinib in axSpA
MILAN, Italy — September 18, 2026 Alfasigma announced that the Committee for Medicinal Products for Human Use (CHMP) of...
Santa Ana Bio Advances SAB01 Into Phase 1
ALAMEDA, Calif. — September 14, 2026 Santa Ana Bio announced that the first cohort has been dosed in the...
Advertisements
Amgen and AstraZeneca Report Positive Phase 3 EoE Data
Thousand Oaks, California, United States, Aug. 27, 2026 Amgen and AstraZeneca have announced positive top-line results from the Phase...
Eupraxia Reports Durable EoE Symptom Improvements With EP-104GI
VANCOUVER, British Columbia, August 13, 202 Eupraxia Pharmaceuticals Inc. reported new symptom-response data from the ongoing Phase 1b/2a portion...
LeonaBio Advances Lasofoxifene in Metastatic Breast Cancer
BOTHELL, Wash., August 12, 2026 LeonaBio, Inc. announced that its lead investigational therapy lasofoxifene will be featured in multiple...
Can-Fite Advances Phase III Programs With FDA and EMA Status
RAMAT GAN, Israel, August 12, 2026 Can-Fite BioPharma Ltd. announced an update on the regulatory status of its two...
CalciMedica Aligns With FDA on Auxora Phase 2b Trial
LA JOLLA, Calif., July 29, 2026 CalciMedica, Inc. has announced a significant regulatory milestone after reaching alignment with the...
Advertisement
